• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ILA

ISLAND PHARMACEUTICALS LIMITED - Charts / Financials

9.52% ! 23.0¢
Market Cap $48.35M  !
Healthcare Biotechnology
Add to My Watchlist

Island Pharmaceuticals Ltd is an Australia-based drug repurposing company. The Company is... Island Pharmaceuticals Ltd is an Australia-based drug repurposing company. The Company is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.More

refresh Created with Sketch. REFRESH
Last update - 15.58pm 22/05/2025 (20 minute delay) ?
Day
Open 21.5¢   Day High 24.0¢   Day Low 21.5¢
Daily Volume 1240738
Bids   Sellers
Number Price Volume   Number Price Volume
4 22.5¢ 30653   1 23.0¢ 2461

Directors & Senior Management

Mr. Phillip Randolph Lynch Executive Chairman
Dr. David C. Foster Chief Executive Officer, Managing Director, Executive Director
Mr. Cameron Jones Chief Financial Officer, Company Secretary
Mr. Albert Hansen Non-Executive Director
Mr. Christopher Ntoumenopoulos Non-Executive Director

Data source: Refinitiv

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
23.0¢ 		Change
0.020(9.52%) 		Mkt cap ! $48.35M
Open High Low Value Volume
21.5¢ 24.0¢ 21.5¢ $281.6K 1.240M

Buyers (Bids)

No. Vol. Price($)
4 30653 22.5¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 2461 1
View Market Depth
Last trade - 16.10pm 22/05/2025 (20 minute delay) ?
Last
23.0¢ 		  Change
0.020 ( 7.03 %)
Open High Low Volume
21.5¢ 23.5¢ 21.5¢ 582058
Last updated 15.58pm 22/05/2025 ?

Top Stories

This stock could have something close to a cure for osteoarthritis. Don’t let it hide under your nose

Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.In the background, Paradigm also has a rare disease clinal asset for Mucopolysaccharidosis (MPS) and early-stage data for acute respiratory d...
Long dormant Provaris, building a hydrogen tanker, eyes new market: CO2 storage Provaris Ltd (ASX:PV1), a decidedly unique ASX stock – it's attempting to build a world first hydrogen storage shipping tanker – has made...
Raiden snaps up 75% of Vuzel gold project in Bulgaria as lithium days put to rest Raiden Resources (ASX:RDN) has all but formally pivoted away from lithium with its move to 75% ownership of the Vuzel gold...
An RBA cut was locked in. Beijing’s identical Tuesday cut spotlights larger macro forces An RBA cut was basically guaranteed. But Beijing’s identical Tuesday move spotlights larger macro forces After seeing countries...
Mayne Pharma nosedive deepens as Cosette mulls scrapping $672M buy-up Mayne Pharma Group (ASX:MYX) has been taking a beating in the markets this week, with company value as much as -33% lower @ today down to $4.34 a share after opening Week 21 at $6.48 @ on second thoughts from Cosette.Listen to the HotCopper podcast for in-depth discussions and insights on all the...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.